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RESUMO
Este estudo estimou a validade de cons-
tructo pelo teste de grupos conhecidos do 
Instrumento para Mensuração do Impacto 
da Doença no Cotidiano do Valvopata 
(IDCV) quanto a sinais e sintomas, função 
ventricular sistólica, fração de ejeção do 
ventrículo esquerdo (FEVE) e qualidade de 
vida relacionada à saúde (QVRS) em 153 
coronariopatas em seguimento ambulato-
rial. Os dados foram obtidos pela aplicação 
do IDCV e das versões brasileiras do The 
Medical Study 36-item Short Form Health 
Survey – SF-36 e MacNew Heart Disease 
Health-related Quality of Life Questionnaire. 
Foi utilizado o teste de Mann-Whitney para 
verificar a capacidade do IDCV em discrimi-
nar o impacto quanto a sinais e sintomas, 
FEVE e disfunção sistólica ventricular, bem 
como o teste de Kruskal-Wallis para verificar 
seu poder de discriminação em relação à 
QVRS. Constatou-se que o IDCV discriminou 
o impacto entre aqueles que pontuaram 
nos quartis (≤Q1, Q1-Q3, ≥Q3) de QVRS. 
Os achados deste estudo contribuem para 
o refinamento do IDCV na mensuração do 
impacto da doença entre coronariopatas.
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ABSTRACT
This study estimated the known groups 
construct validity for the Instrument to 
Measure the Impact of Coronary Disease 
on Patient’s Everyday Life (IDCV) related 
to signs and symptoms, ventricular systolic 
function, left ventricular ejection fraction 
(LVEF) and health-related quality of life 
(HRQoL) in 153 outpatients with coronary 
artery disease. Data was obtained through 
application of IDCV and Brazilian versions 
of the instruments The Medical Study 
36-item Short Form Health Survey – SF-36 
and the MacNew Heart Disease Health-
-related Quality of Life Questionnaire. 
Mann-Whitney test was used to verify the 
ability of IDCV in discriminating impact of 
signs and symptoms, LVEF and ventricular 
systolic dysfunction. Also, the Kruskal-Wallis 
test was used to verify the discrimination 
power of the IDCV in relation to HRQoL. It 
was observed that the IDCV discriminated 
the impact between variables scored in 
HRQOL quartiles (≤Q1, Q1-Q3, ≥Q3). The 
study findings contribute for improvement 
of IDCV in measurement of disease impact 
in coronary artery disease patients.
DESCRIPTORS
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RESUMEN
Este estudio tuvo como objetivo estimar la 
validez de constructo por medio de pruebas en 
grupos conocidos del Instrumento para Medi-
ción del Impacto de la Enfermedad en la vida 
diaria del paciente con valvulopatía, relaciona-
do a la búsqueda de signos y síntomas, función 
ventricular sistólica, fracción de eyección 
ventricular izquierda (FEVI) y la calidad de vida 
relacionada con la salud (CVRS). Fue ejecutado 
en 153 pacientes con enfermedad coronaria 
que realizaban control regular en los consul-
torios externos. La recolección de los datos 
fue a través de la aplicación del instrumento 
específico y de las versiones brasileñas del 
The Medical Study 36-item Short Form Health 
Survey – SF-36 y MacNew Heart Disease 
Health-related Quality of Life Questionnaire. 
Fue utilizado la prueba de Mann-Whitney 
para verificar la capacidad del Instrumento 
para Medición del Impacto de la Enfermedad 
en la vida diaria del paciente con valvulopatía 
y discriminar el impacto en relación con los 
signos y síntomas, la fracción de eyección 
ventricular izquierda (FEVI) y la disfunción 
sistólica ventricular izquierda; así como la 
prueba de Kruskal-Wallis para comprobar el 
poder de discriminación en relación con la 
CVRS. Fue constatado que el IDCV fue capaz 
de discriminar el impacto entre los sujetos que 
puntuaron en los cuartiles (≤Q1, Q1-Q3, ≥Q3) 
de la CVRS. Los resultados del estudio contri-
buyen para el perfeccionamiento del IDCV en 
la medición del impacto de la enfermedad en 
pacientes con enfermedad coronaria.
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INTRODUCTION
Coronary artery disease (CAD) is the major cause of 
adult deaths in developed countries(1). In 2010, DATASUS 
preliminary data evidenced CAD as responsible for 99,408 
deaths, which represents 8.8% of total deaths in Brazil(2).
Besides the economic impact that CAD represents, the 
occurrence of an ischemic event causes important reper-
cussions in an individual’s life. The impact on physical as-
pects has been associated with the presence of symptoms, 
particularly precordial pain, dyspnea and fatigue(3-5). The 
feelings of insecurity, anxiety and depression associated 
with fear of a new event reflect compromised emotional 
aspects. Difficulties in return to work and financial concerns 
are examples of the social impact caused by CAD in an 
individual’s life(3-4).
Consequences of an ischemic event can lead to 
different conceptions about the disease and the treat-
ment and, therefore, differences in subjects’ ways of 
adaptation to the new life condition. Understanding the 
patients’ perception of their illness is fun-
damental to intervening in the way they 
handle being ill, the proposed treatment, 
as well as their capacity to appropriately 
manage the course of their disease. It is 
thought that beliefs about the disease 
and its effects mediate construction of an 
individual’s perception about the disease 
impact and treatment in his life(6).
Assuming that the impact of the disease 
results from the balance between a subject’s 
perception of consequences of the disease 
on the different dimensions of his life, and 
evaluation (good or bad) of those consequences, it is likely 
that those who experience a very negative impact of the 
disease have a worse evaluation of their quality of life(7).
In 2007, an instrument for evaluation of the impact 
of disease in the daily life of patients with valve heart 
disease was created and validated for Brazilian culture. 
The instrument was called the Instrument to Measure 
the Impact of Coronary Disease on Patient’s Everyday Life 
(IDCV) and presented satisfactory measurement properties 
when applied to patients with valvular heart disease(7). 
Although the instrument was developed to measure 
impact among patients with valvular heart disease, the 
refinement of its items resulted in selection of pertinent 
aspects to measuring impact on other cardiac conditions 
with similar symptoms(8).
A previous study showed evidence of IDCV validity and 
reliability when used in patients with CAD(8). However, 
IDCV construct validity through the approach of known 
groups has not been estimated. The known groups vali-
dity is a subtype of the construct validity, based on the 
principle that in certain subjects’ groups, different scores 
are expected when compared to others and the instru-
ment must be sensitive to this difference. Therefore, a 
scale with evidenced validity would be the one capable of 
discriminating the difference between the groups in the 
predicted direction(9).
Considering the importance of providing the scientific 
community with an instrument that enables evaluation of 
the impact of CAD in the daily activities of these patients, 
this study had as main goal to estimate known groups 
construct validity of IDCV in outpatients with CAD. The 
specific goals were to estimate the IDCV capacity in discri-
minating disease impact related to signs and symptoms, 
left ventricular dysfunction, left ventricular ejection frac-
tion (LVEF) and both general and specific health-related 
quality of life (HRQoL).
The findings of this study contribute to the psychometric 
refinement of an instrument constructed in the Brazilian 
culture aimed at measuring heart disease impact in indivi-
duals’ lives, especially regarding sensitivity detection of the 
impact in different situations of CAD severity.
METHOD
Type and location of the study
This was a transversal study of metho-
dological type that investigated methods 
for obtaining, organizing and analyzing 
data intended to develop and validate ins-
truments and research techniques(10). It is 
emphasized that the data from the present 
study derived from a larger study(8), whose 
aim was to evaluate the convergent vali-
dity of the IDCV and the generic, general 
(Medical Study 36-Item Short Form Health 
Survey - SF-36) and specific measures of HRQoL (MacNew 
Heart Disease Health-related Quality of Life Questionnaire 
– MacNew), when applied to outpatients with CAD. The 
study was developed in a Cardiologic Clinic of the University 
of Campinas Hospital.
Subjects
This study included 153 outpatients with CAD of the 
referred setting. For this research, patients selected 
were older than 18 years, with a history of myocardial 
infarction (MI) or angina that occurred for a period longer 
than six months, and who agreed to participate in the 
research by signing the Informed Consent. Patients who 
presented incapacity for effective verbal communication 
were excluded.
Sampling Procedure
The sample was composed of patients treated in the 
referred service that met all inclusion criteria, and none 
of the exclusion criteria, enrolled for the research from 
December 2007 up to January 2009. Since this is a section 
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from a larger study, the sample size was estimated by 
correlation coefficients among the instruments(11), that 
is, between IDCV scores and SF-36 and MacNew domains, 
based on a pilot study sample (n=74). Considering cor-
relation coefficients between 0.30 and 0.40, as well as 
the values of α=0.05 and β=0.10, the sample size was 
estimated at 113 subjects. A loss percentage of 35% 
was adopted, so the final sample size was increased to 
153 subjects.
Data collection
Data collection was performed by one of the resear-
chers, individually, in a private setting after obtaining the 
consent. A method of registering available data on the 
medical chart was used to obtain sociodemographic and 
clinical characteristics: name, hospital registration number, 
date of birth, age, gender, origin, MI or angina diagnosis 
date, presence of previous MI, affected wall, type of tre-
atment, data related to risk factors and associated clinical 
conditions. Data obtained by echocardiography – LVEF 
by the Teichholz method, systolic ventricular dysfunction 
(defined as the presence of isolated or associated abnor-
malities of ventricular wall motion: akinesia, hypokinesia, 
dyskinesia or LVEF <0.58), up to one year prior to data 
collection, were also considered. The interview technique 
was used to gather sociodemographic and clinical data 
not available in the hospital records (education, marital 
status, work status before and after MI, family and indivi-
dual income, signs and symptoms in the last month prior 
to the interview), and also for evaluation of the disease 
impact (IDCV) and the general (SF-36) and specific (Mac-
New) HRQoL.
Data Collection Instruments
Sociodemographic and clinical characterization 
instrument: an instrument previously constructed and 
validated for obtaining sociodemographic and clinical 
data was used(12);
Instrument to Measure the Impact of Coronary Di-
sease on Patient’s Everyday Life (IDCV): an instrument 
constructed in the Brazilian culture to assess the impact 
of valvulopathy in the daily life of valvular heart disease 
patients(7). The concept is that the impact is the product 
of disease repercussions; the assessment of each conse-
quence led to the development of two parts (A and B), 
each with 14 items. Part A is designed to measure the 
degree of impact perceived by the subject in different di-
mensions of life, while Part B was developed to consider 
the evaluation (good or bad) of each one of the conse-
quences noted in Part A. In part A, the patient responds 
to each of the items using a five-point Likert scale which 
ranges from 1 – totally disagree up to 5 – totally agree. 
In part B, a Likert-type scale is used for each item, with 
responses that range from 1 – really bad up to 5 – really 
good. The items are grouped into four factors or domains: 
Physical impact of the disease – symptoms (items 11, 12 
and 13), Impact of the disease in daily activities (5, 7, 9, 
10 and 14), Social and emotional impact of the disease 
(items 2, 3, 4 and 6) and Adaptation to the disease (1 
and 8). To determine the final IDCV score, all items in 
part B are reversed. Items 1, 5 and 8 from Part A that 
correspond to perceptions related to favorable impact, 
have their scores reversed. To calculate the score, each 
item corresponds to the product of the scores obtained 
in Parts A and B of IDCV, generating a minimum score of 1 
and a maximum of 25 for each statement evaluated. The 
closer the score is to 1, the smaller the perceived impact 
by the subject; the closer to 25, the greater the perceived 
impact. The total score is calculated by adding all the pro-
ducts obtained, varying from 14 – 350. High scores mean 
that the patient perceives the negative consequences of 
the disease in his life and that these consequences are, 
in fact, interpreted as negative. Lower scores mean that 
patient does not recognize the disease and treatment 
consequences in his life and, if they occur, they are not 
evaluated as bad. Although this instrument has been 
developed to evaluate beliefs of patients with valvular 
heart disease(7), it was observed that the IDCV can also be 
used to evaluate the impact imposed by cardiac disease 
chronicity(7). A previous study demonstrated its reliability 
and validity for assessment of the disease impact among 
patients with CAD(8). The present study showed satisfac-
tory Cronbach’s alpha coefficients for total score (0.85) 
and for the majority of dimensions - Physical impact of 
the disease – symptoms (0.71), Impact of the disease in 
daily activities (0.72) and Social and emotional impact of 
the disease (0.78). No evaluation of internal consistence 
of the domain Adaptation to the disease was conducted 
because it is composed of two items.
MacNew Heart Disease Health-related Quality of Life 
Questionnaire – MacNew: consists of a modified instru-
ment from the Quality of Life after Myocardial Infarction 
(QLMI) Questionnaire, which was originally developed in 
English for patients who survived a MI and who had an 
indication to participate in a cardiac rehabilitation pro-
gram(12). It is composed of 27 items distributed in three 
domains, with some of the same items being part of more 
than one domain: Physical Limitation (13 items – 6, 9, 12, 
14, 16, 17, 19, 20, 21, 24, 25, 26 e 27), Emotional Function 
(14 items - 1, 2, 3, 4, 5, 6, 7, 8, 10, 13, 15, 18, 23) and 
Social Function (13 items - 2, 11, 12, 13, 15, 17, 20, 21, 
22, 23, 24, 25, 26). The maximum possible score in each 
domain is 7 (better HRQOL) and the minimum is 1 (worst 
HRQoL). Missed responses do not contribute to the 
score and item 27 (sexual intercourse) can be excluded 
without changing the domain score. The domain scores 
are calculated by average responses in that domain. It 
is emphasized that if more than 50% of the items for a 
domain are missing, the score for that domain must not 
be calculated. The instrument also has a total score calcu-
lated as the mean of all items counted, unless one of the 
domains is completely missing(13). This instrument was 
adapted for Brazilian Portuguese (14) and its psychometric 
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performance in the Brazilian culture was evaluated in a 
previous study(10). The present study found evidence of 
reliability for the total score (Cronbach’s alpha = 0.91) 
and for the domains: Physical Function (0.84), Emotional 
Function (0.90) and Social Function (0.84).
The Medical Study 36-item Short Form Health Survey 
– SF-36: comprises a self-administered, and multidimen-
sional questionnaire, consisting of 36 items divided into 
eight scales or components: Physical functioning (10 ite-
ms), Role physical (4 items), Bodily Pain (2 items), General 
Health (5 items), Vitality (4 items), Social Functioning 
(2 items), Mental Health (5 items) and one more ques-
tion of comparative evaluation between current health 
conditions and those from one year ago. The final score 
ranges from 0 up to 100, where 0 corresponds to the 
worst general health status and 100 to the best health 
status(15). The version adapted to the Brazilian culture was 
used(16). This study found evidence of reliability for the 
majority of SF-36 domains (Cronbach’s alpha coefficient 
ranged between 0.64 and 0.92).
Data Analysis
Data was entered into an electronic spreadsheet in 
the Statistical Package for Social Sciences (SPSS) sof-
tware, version 17.0 for Windows, and then transferred 
to the Statistical Analysis System for Windows program, 
version 9.2 (Statistical Analysis System Institute Inc., 
Cary, NC, USA, 2008), to perform the statistical analyses. 
Descriptive analysis was performed with production of 
frequency tables, measures of location and dispersion for 
sociodemographic and clinical data, IDVC and MacNew, 
and SF-36 domains.
To test the IDCV construct validity through the 
method of known groups, the starting point was the 
hypothesis that patients with signs and symptoms 
(precordial pain, dyspnea, lipothymia, palpitations and 
edema) or lowered LVEF (≤0.58, value adopted by the 
service), or with ventricular systolic dysfunction, or 
with greater impairment of HRQoL (those who scored ≤ 
first HRQoL quartile) would present significantly higher 
impact of disease than patients without symptoms, with 
preserved LVEF, without systolic dysfunction and with 
lower HRQoL impairment (who scored ≥ third HRQoL 
quartile), respectively. Thus, scores of the generic and 
specific HRQoL measures were considered as categorical 
variables and groups were assembled using as a cut-off 
point the scores from the first and the third quartile, per 
the example of a previous study(17). Therefore, patients 
with HRQoL scores ≤ Q1, between Q1 and Q3 and ≥ Q3 
were compared. The Mann-Whitney test was used to 
examine differences between two groups (patients with 
or without signs/symptoms - precordial pain, dyspnea, 
palpitations and edema; with normal LVEF or ≤0.58 and 
with or without systolic ventricular dysfunction). The 
Kruskal-Wallis test followed by Dunn’s pos hoc test, were 
used to identify and compare difference between three 
groups, i.e., the patients with CAD that scored in general 
and specific HRQoL quartiles (≤ Q1, Q1-Q3, ≥Q3). Two 
by two differences were lower than 0.05 (p-value <0.05). 
Nonparametric tests were used in comparison analysis 
due to lack of normal distribution of the variables of 
interest. The Shapiro-Wilk test was used to test the nor-
mality. The level of significance of ≤ 0.05 was adopted.
Ethical Aspects
This study was approved by the Ethics in Research 
Committee of the Faculty of Medical Sciences, University 
of Campinas, and it was approved in the Regular Meeting 
VIII on August 24, 2010 (Report no 370/2007). All enrolled 
patients signed the informed consent.
RESULTS
Sociodemographic and Clinical Characterization
There was an observed predominance of men (69.9%), 
mean age of 62.2 (10.1) years, mean schooling of 4.9 years 
(3.9), married (66.7%), retired (70.0%), mean individual 
income of 2.3 (1.9) minimum wages (MW)/month and 
average household income of 3.8 (2.8) MW/month.
The majority of patients (91.5%) had experienced a 
MI (isolated or associated with post-MI angina), mean of 
1.2 (0.8) previous MI and 2.9 (1.1) clinical conditions or 
associated risk factors. All participants reported presence 
of symptoms in the month prior to the interview, with 
mean of 1.3 (1.2) associated symptoms. A mean use of 5.8 
(1.7) medications per day was found. LVEF was lowered 
in 43.7% of the 64 patients with available information 
from hospital records, and 57.8% of the sample had 
systolic dysfunction.
Construct validity by known groups test
Data for comparison of the IDCV scores among pa-
tients with CAD related to clinical variables are presented 
in Table 1.
The results presented in Table 1 revealed that the 
dimensions and the total IDCV score do not discriminate 
in the impact of disease among patients with CAD for the 
presence of signs and symptoms, as well as in relation to 
LVEF and LV systolic function. Therefore, patients with 
lowered LVEF (≤0.58) or with systolic dysfunction had 
similar scores as asymptomatic patients with CAD with 
normal LVEF, and no changes in ventricular systolic func-
tion were observed.
The Kruskal-Wallis test was used to verify the IDCV total 
score capacity and capacity of its dimensions in discrimina-
ting the impact of CAD among general and specific HRQoL 
quartiles. Data related to the comparison of total scores 
and IDCV dimensions according to quartiles (≤ Q1, Q1-Q3, 
≥Q3) of the HRQoL generic measure, assessed by the SF-36, 
are presented in Table 2.
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Except for the domain Adaptation to the disease, lower 
scores were observed in the remaining domains and the 
total IDCV score in Q≥3 in all dimensions from SF-36, which 
demonstrates that the smaller the impact of the disease 
perceived by the patient with CAD, the better their HRQoL.
The Kruskal-Wallis test showed that all of the domains 
and the total IDCV score discriminated differences in the im-
pact of the disease among quartiles of the generic measure 
of HRQoL, except for the domain Adaptation to the disease.
It is noted that all the domains and the IDCV total 
score discriminated the impact of the disease in the SF-36 
domains Bodily pain and General Health, with statistically 
significant differences in all quartiles from those domains 
(≤Q1 ≠ ≥Q3 e Q1-Q3 ≠ ≥Q3 e Q1-Q3 ≠ ≤Q1; p-value<0,0001).
However, the domain Impact of the disease in daily 
activities and the total IDCV score only discriminated diffe-
rences in the impact on the domain Role emotional among 
the patients with CAD who scored in the extreme HRQoL 
quartiles (≤Q1≠ ≥Q3).
Data related to the comparison of the total IDCV scores 
and its dimensions, according to the specific measure of 
HRQoL quartiles, assessed by the application of MacNew, 
are presented in Table 3.
Data in Table 3 indicate, as has been shown in relation 
to the generic HRQoL measure, lower total IDCV and di-
mensions scores in Q≥3 in all the domains and the total 
MacNew score, except for the domain Adaptation to the 
disease, which means that the better the HRQoL, the lower 
the impact of the disease perceived by the individual.
In addition, it was observed that most of the domains 
and total IDCV scores discriminated the impact of the di-
sease among all quartiles from all the MacNew domains 
assessed, except for Adaptation to the disease (p<0.0001; 
Kruskal-Wallis; ≤Q1 ≠ ≥Q3 e Q1-Q3≠ ≥Q3 and Q1-Q3≠ ≤Q1).
Table 1 – IDCV scores according to clinical variables of outpatients with CAD - Campinas, 2010.
Symptoms
Domains and Total IDCV scores
Physical
Impact
Mean (SD)
Impact in
Daily Activities
Mean (SD)
Social and
Emotional Impact
Mean (SD)
Adaptation to the 
disease
Mean (SD)
Total
IDCV
Mean (SD)
Precordial Pain 
(n=145)
Yes
(n = 58)
36.2 (20.3) 58.6 (28.9) 53.0 (27.6) 10.1 (7.5) 158.0 (68.3)
No
(n = 87)
33.0 (19.8) 56.7 (27.9) 47.9 (26.1) 10.6 (7.4) 148.2 (64.7)
p-value* 0.372 0.759 0.247 0.768 0.385
Dyspnea (n=146) Yes
(n = 54)
35.6 (19.5) 56.8 (28.0) 51.2 (28.1) 11.0 (7.6) 154.7 (67.3)
No
(n = 92)
33.6 (20.3) 58.1 (28.4) 49.3 (25.9) 10.1(7.3) 151.1 (65.5)
p-value 0.595 0.852 0.744 0.375 0.753
Palpitation (n=146) Yes 
(n = 33)
34.4 (20.7) 60.0 (27.0) 50.4 (28.1) 9.8 (8.4) 154.7 (68.3)
No
(n=113)
34.4 (19.8) 56.9 (28.5) 49.9 (26.3) 10.6 (7.2) 151.8 (65.6)
p-value 0.897 0.600 0.966 0.371 0.775
Edema (n=83) Yes
(n = 36)
32.4 (19.6) 50.3 (24.9) 43.3 (25.6) 12.1 (8.3) 138.2 (63.4)
No 
(n = 47)
30.5 (19.5) 49.6 (26.3) 45.3 (24.9) 12.9 (7.6) 138.3 (63.5)
p-value 0.636 0.930 0.571 0.515 0.974
Systolic Disfunction
(n=112)
Yes
(n = 68)
38.4 (18.7) 54.8 (28.1) 50.5 (25.4) 11.3 (6.7) 155.1 (65.4)
No 
(n = 44)
33.6 (18.4) 53.6 (27.8) 44.0 (25.0) 12.9 (7.9) 144.1 (63.0)
p-value 0.263 0.940 0.291 0.696 0.536
LVEF† (n=106) Decreased‡
(n = 41)
38.3 (18.8) 53.2 (27.0) 47.3 (25.4) 11.1 (6.8) 149.9 (62.8)
Normal 
(n = 65)
34.9 (18.5) 55.2 (28.7) 48.1 (25.4) 12.6 (7.6) 150.9 (66.1)
p-value 0.392 0.849 0.989 0.526 0.967
*Mann-Whitney test; †Left Ventricular ejection fraction, ‡Left Ventricular ejection fraction ≤0.58. Note: (n=153).
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Table 2 – IDCV scores according to quartiles of HRQOL generic measure (SF-36) from outpatient coronary heart disease - Campinas, 2010
Domains
SF-36
Quartiles
HRQOL
Domains and Total IDCV score
Physical
Impact
Mean (SD)
Daily Activities 
Impact
Mean (SD)
Social and 
Emotional Impact
Mean (SD)
Adaptation to 
disease
Mean (SD)
Total
IDCV
Mean (SD)
Physical functioning ≤Q1 50.3 (18.9) 73.5 (24.5) 62.2 (23.6) 10.2 (7.7) 196.1 (58.9)
Q1-Q3 36.2 (16.1) 61.6 (26.7) 57.2 (26.0) 10.2 (7.2) 165.3 (56.0)
≥Q3 20.2 (12.8) 40.4 (22.5) 32.1 (18.0) 10.7 (7.4) 103.4 (44.6)
p-value* 0.0001(c) 0.0001(c) 0.0001(a) 0.9334 0.0001(c)
Role physical ≤Q1 44.2 (19.5) 69.0 (24.6) 63.6 (23.2) 10.1 (7.6) 186.9 (59.5)
Q1-Q3 29.6 (18.3) 53.4 (29.5) 46.6 (23.7) 10.8 (6.7) 140.4 (61.2)
≥Q3 29.4 (18.2) 49.3 (25.7) 38.0 (25.8) 10.2 (8.0) 126.9 (59.8)
p-value 0.0002(b) 0.0010(b) 0.0001(b) 0.4870 0.0001(b)
Bodily pain ≤Q1 50.9 (16.2) 75.7 (22.6) 67.5 (17.8) 9.6 (7.9) 203.8 (45.4)
Q1-Q3 34.7 (18.5) 59.1 (28.4) 52.4 (26.2) 10.3 (6.9) 156.6 (63.0)
≥Q3 19.9 (12.6) 39.2 (19.6) 29.8 (18.2) 10.9 (7.3) 99.8 (39.5)
p-value 0.0001(c) 0.0001(c) 0.0001(c) 0.5801 0.0001(c)
General health ≤Q1 46.6 (18.5) 72.5 (24.3) 66.7 (21.7) 8.9 (7.1) 194.6 (54.5)
Q1-Q3 33.3 (18.1) 60.5 (27.0) 49.6 (25.2) 11.5 (8.0) 155.0 (60.2)
≥Q3 22.9 (16.5) 35.5 (18.9) 31.3 (19.3) 10.0 (6.2) 99.7 (44.9)
p-value 0.0001(c) 0.0001(c) 0.0001(c) 0.2571 0.0001(c)
Vitality ≤Q1 43.8 (19.7) 72.2 (27.0) 66.0 (24.3) 12.0 (8.4) 194.0 (63.0)
Q1-Q3 36.2 (18.5) 58.7 (23.0) 49.1 (23.8) 9.3 (6.6) 153.5 (54.5)
≥Q3 23.1 (15.4) 41.2 (25.2) 34.1 (20.5) 9.8 (6.8) 108.2 (47.1)
p-value 0.0001(a) 0.0001(c) 0.0001(c) 0.2401 0.0001(c)
Social functioning ≤Q1 46.0 (19.4) 73.3 (24.7) 62.4 (25.3) 9.1 (7.4) 190.9 (61.9)
Q1-Q3 35.7 (18.6) 60.2 (24.8) 54.8 (25.7) 10.3 (7.3) 161.0 (58.8)
≥Q3 24.2 (15.8) 42.5 (25.6) 35.4 (20.5) 11.3 (7.4) 113.5 (51.2)
p-value 0.0001(c) 0.0001(c) 0.0001(a) 0.2294 0.0001(c)
Role emotional ≤Q1 45.0 (17.8) 74.5 (24.5) 65.9 (23.5) 10.3 (7.8) 195.6 (56.1)
Q1-Q3 38.2 (21.2) 61.9 (27.7) 52.5 (23.7) 10.7 (7.3) 163.3 (67.5)
≥Q3 28.1 (18.0) 47.5 (25.3) 40.7 (24.1) 10.3 (7.2) 126.6 (55.9)
p-value 0.0001(d) 0.0001(a) 0.0001(d) 0.9503 0.0001(a)
Mental health ≤Q1 47.6 (18.1) 77.1 (22.2) 64.7 (22.8) 11.0 (8.4) 200.4 (55.4)
Q1-Q3 31.2 (18.1) 57.1 (26.9) 52.6 (26.5) 9.5 (6.9) 150.4 (61.3)
≥Q3 26.8 (18.1) 39.5 (21.7) 31.6 (17.1) 11.1 (7.0) 109.0 (45.5)
p-value 0.0001(b) 0.0001(c) 0.0001(c) 0.3416 0.0001(c)
*Kruskal-Wallis test, followed by Dunn’s pos-hoc test (a)(≤Q1 ≠ ≥Q3 and Q1-Q3 ≠ ≥Q3); (b)(Q1 ≠ ≥Q3 and Q1-Q3 ≠ ≤ Q1); (c)(≤ Q1 ≠ ≥Q3 and Q1-Q3 ≠ ≥Q3 and 
Q1-Q3 ≠ ≤Q1); (d)(≤Q1≠ ≥Q3). Note: (n=153).
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DISCUSSION
This study aimed to estimate the known groups cons-
truct validity of the IDCV in outpatients with coronary 
artery disease. The IDCV capacity in discriminating the 
impact of the disease related to signs and symptoms, left 
ventricular dysfunction, LVEF and HRQOL (general and 
specific) was estimated. The previous hypothesis was that 
the IDCV would discriminate a larger impact of the disease 
among symptomatic patients, with decreased LVEF and 
systolic ventricular dysfunction (evaluated by presence of 
akinesia, hypokinesia, and dyskinesia and/or decreased 
LVEF) and between those who scored in Q≥1 of the gene-
ric and specific measures of HRQoL, when compared to 
asymptomatic patients, with LVEF and ventricular function 
preserved and that scored in Q≤1 of generic and specific 
HRQOL. However, this hypothesis was only partially sup-
ported, since the IDCV was not capable of discriminating 
the impact of the disease related to symptoms, LVEF and 
systolic ventricular dysfunction.
The circumstance that the IDCV did not distinguish the 
impact of the disease related to signs and symptoms can 
be explained by the fact that the sample was composed 
of patients with chronic disease, with absence of acute 
manifestation of the illness, whose interaction with the 
disease over time could have contributed to a better 
adaptation to the clinical repercussions imposed by it 
and, consequently, to the lower perception of the impact 
of the symptoms on daily life. The absence of differences 
in the extent of the impact between the symptomatic and 
asymptomatic groups can also be explained by the fact that 
measures of the impact and evaluation of the symptoms 
had occurred at different moments in time. While the 
evaluation of impact occurred at the time of data collec-
tion, the survey of the signs and symptoms by self-report 
considered report of symptoms up to one month prior 
to the application of IDCV. It is also noted the possibility 
that these results arose from differences in sample size 
between the groups, which were characterized by a higher 
number of asymptomatic patients.
Considering previously reported associations between 
LVEF and HRQoL in patients with CAD(18), the hypothesis was 
that patients with decreased LVEF would present a more 
severe impact of the disease. Thus, it was expected that 
the IDCV would discriminate this impact between groups of 
patients with decreased LVEF and patients with preserved 
LVEF. However, the IDCV did not discriminate the impact 
related to changes in LVEF and systolic ventricular function. 
These findings corroborate the results of a preceding study 
of validation of the specific HRQoL instrument for patients 
with coronary heart disease(8), in which the instrument 
being validated did not discriminate HRQoL between sub-
jects with normal or decreased LVEF, although it was able 
to discriminate HRQoL between subjects with and without 
left ventricular systolic dysfunction. This finding may also be 
attributed to the different time of obtaining data of impact 
(collected during interview) and left ventricular performan-
ce, obtained within one year prior to data collection. Also, a 
lack of consensus in the literature(19) to establish the cut-off 
point of LVEF should be considered. In this study the value 
of 0.58 was used, which does not exclude the possibility of 
bias in the selection of groups.
Furthermore, recent studies investigating the asso-
ciation between HRQOL in heart failure and ventricular 
Table 3 – IDCV scores according to quartiles of the specific HRQoL measure among outpatients with CAD − Campinas, 2010.
Domains 
MacNew
Quartiles 
HRQOL
Domains and total IDCV score
Physical Impact 
Mean (SD)
Daily Activities 
Impact
Mean (SD)
Social and 
Emotional
Impact
Mean (SD)
Adaptation to the 
disease
Mean (SD)
Total
IDCV
Mean (SD)
Physical
Limitation
≤ Q1 50.3 (17.9) 78.6 (18.5) 67.2 (21.4) 11.1 (7.8) 207.3 (49.4)
Q1-Q3 35.3 (17.4) 59.4 (27.6) 51.9 (25.7) 8.7 (6.6) 155.2 (58.6)
≥Q3 17.7 (10.6) 33.5 (15.3) 29.2 (16.1) 12.9 (7.7) 93.2 (32.9)
p-value* 0.0001(a) 0.0001(a) 0.0001(a) 0.0127 0.0001(a)
Social Function ≤ Q1 49.1 (18.2) 76.8 (22.1) 67.5 (21.4) 10.6 (7.9) 203.9 (54.0)
Q1-Q3 32.9 (18.0) 55.6 (26.9) 51.0 (25.1) 9.1 (6.8) 148.7 (59.7)
≥Q3 21.9 (14.8) 40.5 (23.3) 28.6 (16.6) 12.6 (7.5) 103.7 (42.6)
p-value 0.0001(a) 0.0001(a) 0.0001(a) 0.0802 0.0001(a)
Emotional 
Function
≤ Q1 49.6 (17.6) 77.2 (21.9) 67.2 (20.3) 11.0 (8.2) 205.0 (51.5)
Q1-Q3 36.4 (18.1) 59.7 (27.1) 52.4 (25.2) 9.7 (6.8) 158.3 (57.9)
≥Q3 19.0 (12.0) 37.8 (20.3) 31.4 (20.6) 11.0 (7.6) 99.0 (43.9)
p-value 0.0001 0.0001(a) 0.0001(a) 0.5311 0.0001(a)
*Kruskal-Wallis test, followed by Dunn’s pos-hoc test (a)(≤Q1 ≠ ≥Q3 and Q1-Q3 ≠ ≥Q3 and Q1-Q3 ≠ ≤Q1). Note:(n=153)
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CONCLUSION
The findings of this study concluded that total IDCV 
and most of its domains discriminated the impact of the 
disease among groups of patients who scored in different 
quartiles of general and specific HRQoL measures. Yet 
the IDCV did not discriminate the impact of the disease 
related to signs and symptoms (edema, dyspnea, angi-
na and arrhythmias), LVEF and left ventricular systolic 
function. Further research with the inclusion of more 
accurate measures of clinical variables are recommended 
in order to contribute to the refinement of the measure 
provided by the IDCV.
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